Subscribe
shutterstock_1110645284_fahroni
Fahroni / Shutterstock.com
10 July 2020GenericsRory O'Neill

CJEU ‘shuts door’ on SPCs for second medical uses

The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Second medical use: a regulatory perspective
8 February 2021   Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
Big Pharma
SPCs outlive patent protections in 91% of cases, new report reveals
24 June 2021   Supplementary protection certificates outlive medicinal patents in more than nine in ten cases, a new report has found.
Big Pharma
In conversation with...Beatriz San Martin, Arnold & Porter
13 October 2022   The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Europe
Second medical use: a regulatory perspective
8 February 2021   Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
Big Pharma
SPCs outlive patent protections in 91% of cases, new report reveals
24 June 2021   Supplementary protection certificates outlive medicinal patents in more than nine in ten cases, a new report has found.
Big Pharma
In conversation with...Beatriz San Martin, Arnold & Porter
13 October 2022   The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.

More on this story

Europe
Second medical use: a regulatory perspective
8 February 2021   Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
Big Pharma
SPCs outlive patent protections in 91% of cases, new report reveals
24 June 2021   Supplementary protection certificates outlive medicinal patents in more than nine in ten cases, a new report has found.
Big Pharma
In conversation with...Beatriz San Martin, Arnold & Porter
13 October 2022   The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court